Skip to content
Catalyst

N-acetyl-L-cysteineWhat was measured

Measured, with no finding

920 endpoints

Show what was measuredHide what was measured
  • contrast-induced nephropathy, Fisher's Combined Test

    decreases, p = 0.005

    The Fisher's Combined Test was significant at p < 0.005 in favor of N-acetylcysteine

    PMID 15562929 · one of two readings recorded this

  • relative risk reduction in contrast-induced nephropathy

    decreases

    There was a 62% relative risk reduction in contrast-induced nephropathy with N-acetylcysteine using a fixed-effects model

    PMID 15562929 · one of two readings recorded this

  • relative risk reduction in contrast-induced nephropathy

    decreases

    a 70% relative risk reduction using the random-effects model

    PMID 15562929 · one of two readings recorded this

  • size of N-acetylcysteine effect on contrast-induced nephropathy

    decreases

    The size of the N-acetylcysteine effect was to reduce contrast-induced nephropathy by 20%

    PMID 15562929 · one of two readings recorded this

  • unpublished null trials needed to overturn combined significance (Rosenthal method)

    p = 0.005

    we found that 27 unpublished trials showing no effects of N-acetylcysteine would exist to overturn the combined significance of p < 0.005 of the five trials in our meta-analysis

    PMID 15562929 · one of two readings recorded this

  • development of contrast-induced nephropathy

    decreases

    The relative risk of developing contrast-induced nephropathy was 0.43 (95% CI, 0.24 to 0.75) in subjects randomized to N-acetylcysteine

    PMID 15836554 · one of two readings recorded this

  • incidence of dialysis

    The incidence of dialysis was rare (0.2%)

    PMID 15836554 · one of two readings recorded this

  • mean change in creatinine

    decreases

    The difference in mean change in creatinine between the N-acetylcysteine-treated group and controls was -0.27 mg/dl (95% confidence interval [CI], -0.43 to -0.11)

    PMID 15836554 · one of two readings recorded this

  • relative risk of developing contrast-induced nephropathy at 48 hours; mean change in creatinine, NAC versus controls

    RR 0.43, 95% CI 0.24 to 0.75

    Not recorded as a finding: this platform holds no node for the endpoint

    The relative risk of developing contrast-induced nephropathy was 0.43 (95% CI, 0.24 to 0.75) in subjects randomized to N-acetylcysteine.

    PMID 15836554 · one of two readings recorded this

  • average patient age of trials

    p = 0.24

    Patient-related | Age (years) | 68 ± 4 | 70 ± 3 | 0.24

    PMID 18001477 · one of two readings recorded this

  • baseline creatinine of trial populations

    p = 0.09

    Baseline creatinine (mg/dl) | 1.6 ± 0.4 | 2.2 ± 0.6 | 0.09

    PMID 18001477 · one of two readings recorded this

  • CIN rate in control subjects

    increases, p = 0.03

    control subjects experienced more CIN in cluster 2 compared with cluster 1 trials (31% ± 10% versus 12% ± 6%; p = 0.03)

    PMID 18001477 · one of two readings recorded this

  • contrast-induced nephrotoxicity incidence as defined in each trial (serum creatinine rise), relative risk by cluster of trials; change in serum creatinine; dialysis

    no effect, p = 0.28

    Not recorded as a finding: this platform holds no node for the endpoint

    Cluster 1 studies (2445 patients) showed no benefit from NAC administration to prevent CIN (RR = 0.87; 95% CI 0.68–1.12, p = 0.28).

    PMID 18001477 · one of two readings recorded this

  • contrast volume of trial populations

    p = 0.11

    Contrast volume (ml) | 158 ± 61 | 122 ± 46 | 0.11

    PMID 18001477 · one of two readings recorded this

  • correlation of CIN relative risk with dialysis relative risk

    unclear, p = 0.038

    is positively correlated with the RR of requiring dialysis post-contrast (r = 0.66; p = 0.038)

    PMID 18001477 · one of two readings recorded this

  • creatinine decrease in NAC-treated patients of cluster 2 studies

    decreases, p = 0.07

    relatively large creatinine decreases in NAC-treated patients (p = 0.07; open boxes on the right-hand side)

    PMID 18001477 · one of two readings recorded this

  • creatinine increase in control patients of cluster 2 studies

    increases, p = 0.02

    these four studies have relatively large creatinine increases in control patients (p = 0.02; open boxes on the left-hand side)

    PMID 18001477 · one of two readings recorded this

  • diabetes prevalence of trial populations

    p = 0.93

    Diabetes mellitus (%) | 43 ± 13 | 45 ± 13 | 0.93

    PMID 18001477 · one of two readings recorded this

  • dialysis after contrast, all 22 trials

    no effect, p = 0.42

    A total of 13 patients received dialysis post-contrast (control n = 5, NAC-treated n = 8; p = 0.42)

    PMID 18001477 · one of two readings recorded this

  • dialysis after contrast, cluster 1

    no effect, p = 0.26

    cluster 1 (control n = 4, NAC-treated n = 8; p = 0.26)

    PMID 18001477 · one of two readings recorded this

  • dialysis after contrast, cluster 2

    no effect, p = 1

    cluster 2 (control n = 1, NAC-treated n = 0; p = 1.0)

    PMID 18001477 · one of two readings recorded this

  • dialysis after contrast, pooled risk ratio

    no effect, p = 0.54

    NAC treatment showed no evidence of being protective using the clinical endpoint of dialysis events (RR = 1.42; CI 0.46–4.39, p = 0.54)

    PMID 18001477 · one of two readings recorded this

  • difference in treatment effect between cluster 1 and cluster 2

    modulates, p = 0.0001

    these two sets of trials were found to have significantly different treatment effects (p < 0.0001)

    PMID 18001477 · one of two readings recorded this

  • female proportion of trial populations

    p = 0.31

    Female (%) | 31 ± 14 | 22 ± 9 | 0.31

    PMID 18001477 · one of two readings recorded this

  • heterogeneity among 22 trials for contrast-induced nephrotoxicity (CIN)

    unclear, p = 0.04, n = 2746

    significant heterogeneity (I2 = 37%; p = 0.04)

    PMID 18001477 · one of two readings recorded this

  • incidence of contrast-induced nephrotoxicity (CIN)

    no effect, p = 0.28, n = 2445

    Cluster 1 studies (2445 patients) showed no benefit from NAC administration to prevent CIN (RR = 0.87; 95% CI 0.68–1.12, p = 0.28)

    PMID 18001477 · one of two readings recorded this

  • incidence of contrast-induced nephrotoxicity (CIN)

    decreases, p = 0.0001, n = 301

    Cluster 2 studies (301 patients) indicated a large benefit from NAC treatment (RR = 0.15; CI 0.07–0.33, p < 0.0001)

    PMID 18001477 · one of two readings recorded this

  • incidence of contrast-induced nephrotoxicity (CIN)

    no effect, p = 0.35, n = 3268

    showed no benefit of NAC for preventing CIN (RR = 0.90; 95% CI 0.72–1.12, p = 0.35)

    PMID 18001477 · one of two readings recorded this

  • Jadad score of trials

    p = 0.24

    Jadad score (1–5) | 2.9 ± 1.5 | 2.0 ± 1.4 | 0.24

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on age

    no effect, p = 0.56

    Patient-related | Age (years) | -0.13 | 0.56

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on baseline creatinine

    no effect, p = 0.96

    Baseline Creatinine (mg/dl) | -0.01 | 0.96

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on CIN event rate in control group

    no effect, p = 0.35

    CIN event rate in control group (%) | 0.21 | 0.35

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on contrast volume

    no effect, p = 0.24

    Contrast volume (ml) | -0.27 | 0.24

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on diabetes prevalence

    no effect, p = 0.31

    Diabetes mellitus (%) | -0.23 | 0.31

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on female proportion

    no effect, p = 0.72

    Female (%) | 0.1 | 0.72

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on Jadad score

    no effect, p = 0.75

    Jadad score (1–5) | 0.07 | 0.75

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on publication date

    no effect, p = 0.1

    Study-related | Publication date (months after first) | 0.36 | 0.1

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on study size

    no effect, p = 0.54

    Study size (number of patients) | 0.14 | 0.54

    PMID 18001477 · one of two readings recorded this

  • meta-regression of NAC efficacy on total NAC dose

    no effect, p = 0.25

    Total NAC dose (mg) | -0.26 | 0.25

    PMID 18001477 · one of two readings recorded this

  • publication date of studies

    p = 0.05

    Study-related | Publication date (months after first) | 38 ± 8 | 22 ± 17 | 0.05

    PMID 18001477 · one of two readings recorded this

  • study size of trials

    p = 0.23

    Study size (number of patients) | 136 ± 106 | 75 ± 35 | 0.23

    PMID 18001477 · one of two readings recorded this

  • three study factors combined

    p = 0.01

    All three factors combined | 34 ± 13 | 50 ± 9 | 0.01

    PMID 18001477 · one of two readings recorded this

  • acute renal injury after cardiac surgery, absolute serum creatinine rise above 0.5 mg/dL or relative rise above 25% within 5 days, pooled relative risk for perioperative NAC versus placebo

    RR 0.91, 95% CI 0.79-1.06, p = 0.24

    Not recorded as a finding: the paper never states the instrument the node requires

    N-Acetylcysteine did not reduce ARI incidence [35% NAC vs. 37% placebo; relative risk (RR) 0.91, 95% CI 0.79-1.06, P = 0.24].

    PMID 19282300 · one of two readings recorded this

  • acute renal injury (ARI) incidence

    no effect, p = 0.24, n = 1163

    N-Acetylcysteine did not reduce ARI incidence [35% NAC vs. 37% placebo; relative risk (RR) 0.91, 95% CI 0.79-1.06, P = 0.24]

    PMID 19282300 · one of two readings recorded this

  • acute renal injury (ARI) incidence

    unclear, p = 0.06

    There was a trend towards reduced ARI incidence among patients with baseline chronic kidney disease assigned to intravenous NAC (RR = 0.80, 95% CI 0.64-1.01, P = 0.06)

    PMID 19282300 · one of two readings recorded this

  • death

    no effect

    3% died (RR = 1.10, 95% CI 0.56-2.16)

    PMID 19282300 · one of two readings recorded this

  • haemodialysis requirement

    no effect

    Overall, 3.3% of patients required haemodialysis (NAC vs. placebo; RR = 1.13, 95% CI 0.59-2.17)

    PMID 19282300 · one of two readings recorded this

  • heterogeneity of POAF incidence across trials

    no effect, p = 0.366

    with little statistical heterogeneity between the trials (I2 = 8.3%, heterogeneity P = 0.366)

    PMID 22364379 · one of two readings recorded this

  • hospital length of stay in days, pooled WMD

    WMD -0.07, 95% CI -0.42 to 0.28, p = 0.703

    Not recorded as a finding: one-sided negation ('did not significantly reduce'), not a two-sided null

    The pooled analysis using a fixed-effects model showed that NAC supplementation did not significantly reduce LOS (WMD -0.07, 95% CI -0.42 to 0.28; P = 0.703; Figure 3), with no statistical heterogeneity between the trials (I2 = 0.0%, heterogeneity P = 0.922).

    PMID 22364379 · one of two readings recorded this

  • hospital length of stay (LOS)

    no effect, p = 0.703, n = 283

    NAC supplementation did not significantly reduce LOS (WMD -0.07, 95% CI -0.42 to 0.28; P = 0.703; Figure 3)

    PMID 22364379 · one of two readings recorded this

  • hospital length of stay, weighted mean difference, days

    WMD -0.07, 95% CI -0.42 to 0.28, p = 0.703

    Not recorded as a finding: one-sided negation (did not significantly reduce); no two-sided statement in the sentence

    The pooled analysis using a fixed-effects model showed that NAC supplementation did not significantly reduce LOS (WMD -0.07, 95% CI -0.42 to 0.28; P = 0.703; Figure 3), with no statistical heterogeneity between the trials (I2 = 0.0%, heterogeneity P = 0.922).

    PMID 22364379 · one of two readings recorded this

  • incidence of postoperative atrial fibrillation (POAF)

    decreases, p = 0.021, n = 578

    NAC supplementation significantly reduced the incidence of POAF (OR 0.62, 95% CI 0.41 to 0.93; P = 0.021; Figure 2)

    PMID 22364379 · one of two readings recorded this

  • incidence of postoperative atrial fibrillation (POAF)

    decreases, n = 578

    Pooling all eight randomized trials, 28.4% (82 of 289) of patients given NAC and 36.0% (104 of 289) of controls developed POAF

    PMID 22364379 · one of two readings recorded this

  • incidence of postoperative atrial fibrillation (POAF)

    decreases, p = 0.005

    The pooled results didn't significantly change when this trial was excluded (OR 0.52, 95% CI 0.33 to 0.82; P = 0.005)

    PMID 22364379 · one of two readings recorded this

  • POAF events per trial

    n = 100

    El-Hamamsy et al. | CABG | RCT (prospective) | Placebo | Yes | 3 | 4/50 | 6/50 | 5.4 ± 2.3 | 5.3 ± 2.5

    PMID 22364379 · one of two readings recorded this

  • POAF events per trial

    n = 20

    Eren et al. | CABG | RCT (prospective) | Placebo | Yes | 3 | 2/10 | 1/10 | NA | NA

    PMID 22364379 · one of two readings recorded this

  • POAF events per trial

    n = 60

    Haase et al. # | CABG and/or valve | RCT | Placebo | Yes | 5 | 19/30 | 16/30 | 8(7-11) | 8(7-11)

    PMID 22364379 · one of two readings recorded this

  • POAF events per trial

    n = 48

    Kim et al. | CABG | RCT | Placebo | Yes | 4 | 4/24 | 8/24 | 11.3 ± 6.3 | 10.5 ± 4.5

    PMID 22364379 · one of two readings recorded this

  • POAF events per trial

    n = 20

    Orhan et al. | CABG | RCT | Routine protocol | No | 3 | 0/10 | 1/10 | 7.2 ± 0.42 | 7.3 ± 0.48

    PMID 22364379 · one of two readings recorded this

  • POAF events per trial

    n = 115

    Ozaydin et al. | CABG and/or valve | RCT (prospective) | Placebo | Yes | 4 | 3/58 | 12/57 | 7.7 ± 3 | 7.9 ± 4.2

    PMID 22364379 · one of two readings recorded this

  • POAF events per trial

    n = 40

    Peker et al. | CABG | RCT (prospective) | Placebo | Yes | 4 | 0/19 | 2/21 | NA | NA

    PMID 22364379 · one of two readings recorded this

  • POAF events per trial

    n = 175

    Wijeysundera et al. | CABG and/or valve | RCT | Placebo | Yes | 5 | 50/88 | 58/87 | NA | NA

    PMID 22364379 · one of two readings recorded this

  • publication bias for POAF odds ratio (Egger's test)

    no effect, p = 0.275

    Egger's test, P = 0.275; Begg's test, P = 0.536

    PMID 22364379 · one of two readings recorded this

  • length of stay (hospital or ICU not specified), duration of mechanical ventilation, incidence of new organ failure

    no effect

    Not recorded as a finding: one sentence covers three endpoints with no estimates; length of stay does not say hospital or ICU so no node can be chosen; ventilation duration left unrecorded as the sentence carries no estimate

    Neither did N-acetylcysteine show any significant effect on length of stay, duration of mechanical ventilation or incidence of new organ failure.

    PMID 22972094 · one of two readings recorded this

  • mortality in adults with SIRS or sepsis given intravenous NAC versus placebo, pooled risk ratio

    no effect, RR 1.06, 95% CI 0.79 to 1.42

    Not recorded as a finding: the paper never states the instrument the node requires

    Mortality was similar in the N-acetylcysteine group and the placebo group (RR 1.06, 95% CI 0.79 to 1.42; I(2) = 0%).

    PMID 22972094 · one of two readings recorded this

  • Mortality

    no effect, n = 2768

    Mortality was similar in the N-acetylcysteine group and the placebo group (RR 1.06, 95% CI 0.79 to 1.42; I(2) = 0%)

    PMID 22972094 · one of two readings recorded this

  • 1-year mortality

    no effect, p = 0.67

    which was not significantly lower among NAC recipients (15.4% vs. 21.4%, NAC vs. control, respectively, P = 0.67)

    PMID 23383076 · one of two readings recorded this

  • Contrast-induced nephropathy (CIN), pooled risk ratio

    no effect, p = 0.06, n = 1914

    The overall pooled risk ratio (RR) of CIN using a random-effects model was 0.68 (95% CI, 0.45–1.02, p = 0.06)

    PMID 23383076 · one of two readings recorded this

  • Contrast-induced nephropathy (CIN), pooled risk ratio

    no effect, p = 0.12

    The summary risk ratio for CIN associated with the use of NAC was essentially unchanged at 0.72 (95% CI, 0.47–1.09, p = 0.12)

    PMID 23383076 · one of two readings recorded this

  • Contrast-induced nephropathy (CIN), pooled risk ratio

    decreases, p = 0.04

    (RR = 0.59; 95% CI, 0.36–0.97, p = 0.04)

    PMID 23383076 · one of two readings recorded this

  • Contrast-induced nephropathy (CIN), pooled risk ratio

    no effect, p = 0.2

    demonstrated no benefit for NAC with a summary risk ratio of 0.77 (95% CI, 0.50–1.15, p = 0.20)

    PMID 23383076 · one of two readings recorded this

  • In-hospital mortality, pooled relative risk

    no effect, p = 0.29

    The pooled relative risk of in-hospital mortality with intravenous NAC in the four trials was 0.67 (95% CI, 0.32–1.40, P = 0.29)

    PMID 23383076 · one of two readings recorded this

  • Incidence of CIN, average across studies

    The incidence of CIN in the control group ranged from 5.9% to 23.8% with an average of 14.3%

    PMID 23383076 · one of two readings recorded this

  • Incidence of CIN, average across studies

    The incidence of CIN in the treatment group ranged from 2.5% to 16.0% with an average of 7.9%

    PMID 23383076 · one of two readings recorded this

  • incidence of contrast-induced nephropathy, rise in serum creatinine of at least 0.5 mg/dL or 25% above baseline after contrast exposure, pooled risk ratio for intravenous NAC

    RR 0.68, 95% CI 0.45-1.02, p = 0.06

    Not recorded as a finding: this platform holds no node for the endpoint

    The overall pooled risk ratio (RR) of CIN using a random-effects model was 0.68 (95% CI, 0.45–1.02, p = 0.06), indicating a nonsignificant trend towards benefit in patients who received NAC.

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on allocation concealment

    no effect, p = 0.17

    Allocation concealment † | 0.73 | −0.38 to 1.85 | 0.17

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on baseline creatinine

    no effect, p = 0.16

    Baseline Creatinine | −1.02 | −2.5 to 0.50 | 0.16

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on contrast volume

    no effect, p = 0.92

    Contrast volume | −0.08 | −1.91 to 1.75 | 0.92

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on diabetes mellitus

    no effect, p = 0.83

    Diabetes mellitus | −0.01 | −0.08 to 0.07 | 0.83

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on double-blinding

    no effect, p = 0.17

    Double-blinding † | 0.66 | −0.35 to 1.66 | 0.17

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on intention to treat analysis

    no effect, p = 0.45

    Intention to treat analysis † | −0.42 | −1.67 to 0.82 | 0.45

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on Jadad score

    no effect, p = 0.59

    Jadad score | 0.13 | −0.39 to 0.64 | 0.59

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on publication date

    no effect, p = 0.8

    Publication date | −0.02 | −0.18 to 0.15 | 0.80

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on study size

    no effect, p = 0.08

    Study size | 0.98 | −0.12 to 2.07 | 0.08

    PMID 23383076 · one of two readings recorded this

  • Meta-regression of CIN relative risk on total NAC dose

    no effect, p = 0.58

    Total NAC dose | −0.04 | −0.20 to 0.12 | 0.58

    PMID 23383076 · one of two readings recorded this

  • Renal failure requiring dialysis, pooled risk ratio

    no effect, p = 0.72

    The pooled risk ratio of renal failure requiring dialysis was 0.72 (95% CI, 0.34 to 4.75, P = 0.72)

    PMID 23383076 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.03

    Use of NAC was associated with a reduction in all-cause death (OR 0.40; 95% CI 0.17 to 0.93; P = 0.03

    PMID 24739515 · one of two readings recorded this

  • all-cause mortality, pooled OR in cardiac surgery

    decreases, OR 0.40; 95% CI 0.17 to 0.93, p = 0.03

    Not recorded as a finding: all-cause-mortality node requires the follow-up horizon to be recorded and the paper states none for the pooled estimate

    Use of NAC was associated with a reduction in all-cause death (OR 0.40; 95% CI 0.17 to 0.93; P = 0.03; I2 = 0%, Pheterogeneity =0.44; Figure 6).

    PMID 24739515 · one of two readings recorded this

  • All-cause mortality, pooled proportion

    decreases

    Death occurred in 5 of 513 patients (0.9%) treated with NAC and in 16 of 513 patients (3.1%) treated with placebo

    PMID 24739515 · one of two readings recorded this

  • Cerebrovascular events, pooled proportion

    no effect

    Cerebrovascular events occurred in 8 of 423 patients (1.9%) treated with NAC and in 5 of 424 patients (1.2%) treated with placebo

    PMID 24739515 · one of two readings recorded this

  • Cerebrovascular events

    no effect, p = 0.32

    Prophylactic use of NAC failed to present a reduction in cerebrovascular accidents (OR 1.68; 95% CI 0.60 to 4.69; P = 0.32

    PMID 24739515 · one of two readings recorded this

  • hospital length of stay, pooled WMD

    WMD 0.09; 95% CI -0.13 to 0.31, p = 0.4

    Not recorded as a finding: one-sided negation ('did not reduce'), not a two-sided null

    The meta-analysis of the five studies using a fixed-effects model presented that NAC treatment did not reduce the length of hospital stay (WMD 0.09; 95% CI −0.13 to 0.31; P = 0.40; Figure 5).

    PMID 24739515 · one of two readings recorded this

  • hospital length of stay, weighted mean difference, days

    WMD 0.09; 95% CI -0.13 to 0.31, p = 0.4

    Not recorded as a finding: one-sided negation (did not reduce); no two-sided statement in the sentence

    The meta-analysis of the five studies using a fixed-effects model presented that NAC treatment did not reduce the length of hospital stay (WMD 0.09; 95% CI −0.13 to 0.31; P = 0.40; Figure 5).

    PMID 24739515 · one of two readings recorded this

  • ICU length of stay, pooled WMD in hours

    WMD 0.60; 95% CI -0.97 to 2.16, p = 0.45

    Not recorded as a finding: one-sided negation ('not associated with a reduction'), not a two-sided null

    Prophylactic NAC was not associated with a reduction in ICU length of stay (WMD 0.60; 95% CI −0.97 to 2.16; P = 0.45).

    PMID 24739515 · one of two readings recorded this

  • ICU length of stay, weighted mean difference, hours

    WMD 0.60; 95% CI -0.97 to 2.16, p = 0.45

    Not recorded as a finding: one-sided negation (not associated with a reduction); no two-sided statement in the sentence

    Prophylactic NAC was not associated with a reduction in ICU length of stay (WMD 0.60; 95% CI −0.97 to 2.16; P = 0.45).

    PMID 24739515 · one of two readings recorded this

  • incidence of cerebrovascular events after cardiac surgery (nonfatal), odds ratio

    OR 1.68; 95% CI 0.60 to 4.69, p = 0.32

    Not recorded as a finding: no stroke-incidence node match on stated definition and one-sided negation (failed to present a reduction)

    Prophylactic use of NAC failed to present a reduction in cerebrovascular accidents (OR 1.68; 95% CI 0.60 to 4.69; P = 0.32; I2 = 0%, Pheterogeneity =0.64).

    PMID 24739515 · one of two readings recorded this

  • incidence of cerebrovascular events, pooled OR

    OR 1.68; 95% CI 0.60 to 4.69, p = 0.32

    Not recorded as a finding: no outcome node for cerebrovascular events (stroke-incidence node is a different adjudicated endpoint) and one-sided negation

    Prophylactic use of NAC failed to present a reduction in cerebrovascular accidents (OR 1.68; 95% CI 0.60 to 4.69; P = 0.32; I2 = 0%, Pheterogeneity =0.64).

    PMID 24739515 · one of two readings recorded this

  • Incidence of postoperative atrial fibrillation (POAF), pooled proportion

    decreases

    Pooling all ten RCTs, 20.5% (105 of 513) of patients given NAC and 28.8% (148/513) of controls developed POAF

    PMID 24739515 · one of two readings recorded this

  • Incidence of postoperative atrial fibrillation (POAF)

    decreases, p = 0.001, n = 1026

    NAC reduced the incidence of POAF (OR 0.56, 95% CI 0.40 to 0.77; P < 0.001

    PMID 24739515 · one of two readings recorded this

  • Incidence of postoperative atrial fibrillation (POAF)

    decreases, p = 0.001

    The meta-analysis of the remaining studies (OR 0.57, 95% CI 0.40 to 0.80; P = 0.001)

    PMID 24739515 · one of two readings recorded this

  • Incidence of postoperative atrial fibrillation (POAF)

    decreases, p = 0.001

    A trial enrolled some patients with a history of AF, but the pooled results (OR 0.50; 95% CI 0.35 to 0.71; P < 0.001

    PMID 24739515 · one of two readings recorded this

  • Incidence of postoperative atrial fibrillation (POAF)

    decreases, p = 0.001

    (OR 0.40; 95% CI 0.25 to 0.65; P < 0.001; I2 = 22%, Pheterogeneity =0.28; Figure 3)

    PMID 24739515 · one of two readings recorded this

  • Incidence of postoperative atrial fibrillation (POAF)

    no effect, p = 0.09

    it failed to reduce the incidence of POAF with a short-term NAC (within 24 h after surgery) supplementation (OR 0.64; 95% CI 0.39 to 1.06; P = 0.09

    PMID 24739515 · one of two readings recorded this

  • Length of hospital stay

    no effect, p = 0.4

    NAC treatment did not reduce the length of hospital stay (WMD 0.09; 95% CI −0.13 to 0.31; P = 0.40

    PMID 24739515 · one of two readings recorded this

  • Length of ICU stay

    no effect, p = 0.45

    Prophylactic NAC was not associated with a reduction in ICU length of stay (WMD 0.60; 95% CI −0.97 to 2.16; P = 0.45)

    PMID 24739515 · one of two readings recorded this

  • Adverse events (risk of side-effects)

    no effect, p = 0.4

    NAC did not significantly increase the risk of side-effects (relative risk 0.94, 95% CI 0.88–0.99; p=0.40)

    PMID 26324807 · one of two readings recorded this

  • Adverse events (risk of side-effects)

    no effect, p = 0.58

    high doses relative risk 1.11, 95% CI 0.89–1.39; p=0.58

    PMID 26324807 · one of two readings recorded this

  • Adverse events (risk of side-effects)

    no effect, p = 0.4

    low doses relative risk 0.93, 95% CI 0.89–0.97; p=0.40

    PMID 26324807 · one of two readings recorded this

  • Adverse events (risk of side-effects)

    no effect, p = 0.21

    Jadad score ≤3, five studies: treated n=521, placebo n=513; relative risk 0.85, 95% CI 0.47–1.53; p=0.21

    PMID 26324807 · one of two readings recorded this

  • Frequency of COPD exacerbations

    decreases, p = 0.01, n = 4155

    significantly reduced the frequency of exacerbations (relative risk 0.75, 95% CI 0.66–0.84; p<0.01)

    PMID 26324807 · one of two readings recorded this

  • Frequency of COPD exacerbations

    decreases, p = 0.03

    treated n=635, placebo or controls n=1362) and showed a significant reduction of COPD exacerbation rate (relative risk 0.65, 95% CI 0.49–0.88; p=0.03)

    PMID 26324807 · one of two readings recorded this

  • Frequency of COPD exacerbations

    decreases, p = 0.04

    two studies: treated n=534, placebo n=538; relative risk 0.75, 95% CI 0.68–0.82; p=0.04

    PMID 26324807 · one of two readings recorded this

  • Frequency of COPD exacerbations

    decreases, p = 0.01

    treated n=1298, placebo or controls n=1614) significantly protected against COPD exacerbations (relative risk 0.76, 95% CI 0.65–0.89; p<0.01)

    PMID 26324807 · one of two readings recorded this

  • Frequency of COPD exacerbations

    decreases, p = 0.01

    relative risk 0.90, 95% CI 0.84–0.96; p<0.01) in the analysis of those RCTs where COPD was diagnosed using PFT (patients from five studies: treated n=444, placebo n=433)

    PMID 26324807 · one of two readings recorded this

  • Frequency of COPD exacerbations

    decreases, p = 0.01

    seven studies: treated n=978, placebo n=971; relative risk 0.78, 95% CI 0.65–0.93; p<0.01

    PMID 26324807 · one of two readings recorded this

  • Frequency of COPD exacerbations

    decreases, p = 0.01

    seven studies: treated n=957, placebo n=955; relative risk 0.85, 95% CI 0.74–0.98; p<0.01

    PMID 26324807 · one of two readings recorded this

  • Frequency of COPD exacerbations

    decreases, p = 0.07

    six studies: treated n=986, placebo n=1267; relative risk 0.64, 95% CI 0.56–0.74; p=0.07

    PMID 26324807 · one of two readings recorded this

  • Serious adverse events

    no effect, p = 0.81

    eight studies: treated n=1272, placebo n=1267; relative risk 0.95 95% CI 0.67–1.34; p=0.81

    PMID 26324807 · one of two readings recorded this

  • change in 6 minute walk test distance (6MWT), pooled SMD, idiopathic pulmonary fibrosis; also change in %VC, FVC, %DLco, adverse events, death

    SMD = 0.25, 95% CI: 0.02-0.48, p = 0.04

    Not recorded as a finding: another reason, stated per paper

    The decline in 6MWT was significantly less in the N-acetylcysteine group (SMD = 0.25, 95% CI: 0.02–0.48; P = 0.04).

    PMID 27175674 · one of two readings recorded this

  • Change in 6-minute walk test distance (Δ6MWT)

    increases, p = 0.04

    Fixed model: 148 of acetylcysteine, 146 of control, SMD = 0.25, 95% CI 0.02–0.48, P = 0.04

    PMID 27175674 · one of two readings recorded this

  • Change in forced vital capacity (ΔFVC)

    no effect, p = 0.52

    Fixed model: 191 of acetylcysteine, 188 of control, SMD = 0.07, 95% CI −0.13–0.27, P = 0.52

    PMID 27175674 · one of two readings recorded this

  • Change in percentage of predicted carbon monoxide diffusing capacity (Δ%DLco)

    no effect, p = 0.18

    Fixed model: 242 of acetylcysteine, 232 of control, SMD = 0.12, 95% CI −0.06–0.30, P = 0.18

    PMID 27175674 · one of two readings recorded this

  • change in percentage of predicted vital capacity, change in forced vital capacity, change in percentage of predicted DLco, change in 6-minute walk test distance (SMD), pooled in IPF

    decreases, SMD = 0.37, 95% CI 0.13 to -0.62, p = 0.003

    Not recorded as a finding: this platform holds no node for the endpoint

    The decrease in %VC was significantly less in the N-acetylcysteine group than in the control group (SMD = 0.37, 95% CI: 0.13 to −0.62; P = 0.003).

    PMID 27175674 · one of two readings recorded this

  • Change in percentage of predicted vital capacity (Δ%VC)

    increases, p = 0.003

    Fixed model: 130 of acetylcysteine, 129 of control, SMD = 0.37, 95% CI 0.13–0.62, P = 0.003

    PMID 27175674 · one of two readings recorded this

  • Rate of adverse events

    no effect, p = 0.35

    Random model: 177 of acetylcysteine, 177 of control, OR = 4.5, 95% CI 0.19–106.41, P = 0.35

    PMID 27175674 · one of two readings recorded this

  • Rate of death

    no effect, p = 0.28

    Random model: 286 of acetylcysteine, 278 of control, OR = 1.79, 95% CI 0.63–5.12, P = 0.28

    PMID 27175674 · one of two readings recorded this

  • Craving symptoms in substance abuse disorders

    decreases, n = 245

    The result was derived from pooled analysis of 7 randomised control trials with heterogeneous methodology and a small sample size of 245

    PMID 30426004 · one of two readings recorded this

  • Depressive symptoms in unipolar depression

    decreases, n = 252

    In this double-blind, placebo-controlled trials with 252 participants, N-acetylcysteine treatment of 2000 mg/day significantly improved depressive symptoms over the 16 weeks trial period compared to placebo

    PMID 30426004 · one of two readings recorded this

  • Severity of obsessive-compulsive symptoms

    no effect, n = 40

    Costa et al. did not find any significant benefit of N-acetylcysteine in reducing the severity of obsessive-compulsive symptoms among 40 treatment-resistant adults in a 16-week double-blind, placebo-controlled study of N-acetylcysteine (3,000 mg/day)

    PMID 30426004 · one of two readings recorded this

  • Total and negative symptoms of schizophrenia

    decreases, n = 46

    Those treated with N-acetylcysteine (1000 mg/day in the first week increasing to 2000 mg/day for 7 weeks) achieved statistically significant improvements in the total and negative symptoms of schizophrenia compared to those on placebo, over the 8-week period

    PMID 30426004 · one of two readings recorded this

  • allergic adverse events

    no effect, n = 336

    or allergic adverse events (2% versus 0%, RR 2.98, 95% CI 0.32 to 27.74; participants = 336; studies = five; very low-certainty evidence)

    PMID 30746681 · one of two readings recorded this

  • gastrointestinal adverse events

    no effect, n = 336

    whether NAC is associated with a higher risk of gastrointestinal adverse events compared to control (23.9% versus 18.9%, RR 1.25, 95% CI 0.85 to 1.85; participants = 336; studies = five; very low-certaintyevidence)

    PMID 30746681 · one of two readings recorded this

  • H pylori eradication rate

    no effect, n = 559

    (38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low-certainty evidence)

    PMID 30746681 · one of two readings recorded this

  • H pylori eradication rate

    increases, n = 397

    the addition of NAC may improve eradication rates compared to control (27.2% versus 37.6%, RR 0.71, 95% CI 0.53 to 0.94; participants = 397; published studies = five)

    PMID 30746681 · one of two readings recorded this

  • Helicobacter pylori eradication rate, NAC added to antibiotic regimen versus the same regimen with placebo or no NAC, pooled risk ratio

    RR 0.74, 95% CI 0.51 to 1.08, n = 559

    Not recorded as a finding: a direction is stated and the estimate does not support it

    We are uncertain whether the addition of NAC to antibiotics improves H pylori eradication rates, compared with the addition of placebo or no NAC (38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low-certainty evidence).

    PMID 30746681 · one of two readings recorded this

  • Helicobacter pylori eradication rate with NAC added to antibiotics versus antibiotics with placebo or no NAC, eight randomised trials

    RR 0.74, 95% CI 0.51 to 1.08 (38.8% versus 49.1%), n = 559

    Not recorded as a finding: the direction is carried only as a signed number

    We are uncertain whether the addition of NAC to antibiotics improves H pylori eradication rates, compared with the addition of placebo or no NAC (38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low-certainty evidence).

    PMID 30746681 · one of two readings recorded this

  • adverse events event counts (GRADE profile)

    no effect

    4 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 7/237 (3.0%) | 15/227 (6.6%) | RR 0.45 (0.20 to 1.00) | 36 fewer per 1,000 (from 0 fewer to 53 fewer) | ⨁⨁⨁⨁ High | Important

    PMID 31044749 · one of two readings recorded this

  • adverse events rate

    no effect, p = 0.05

    There was no significant difference in simethicone and water group (RR = 0.45, 95%CI: 0.2–1.0, P = 0.05, I2= 0%)

    PMID 31044749 · one of two readings recorded this

  • positive findings event counts (GRADE profile)

    no effect

    3 | Randomized trials | Not serious | Serious* | Not serious | Not serious | None | 270/1879 (14.4%) | 235/1872 (12.6%) | RR 1.13 (0.82 to 1.55) | 16 more per 1,000 (from 23 fewer to 69 more) | ⨁⨁⨁◯ Moderate | Critical

    PMID 31044749 · one of two readings recorded this

  • positive findings event counts (GRADE profile)

    no effect

    3 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 252/717 (35.1%) | 265/783 (33.8%) | RR 1.02 (0.90 to 1.16) | 7 more per 1,000 (from 34 fewer to 54 more) | ⨁⨁⨁⨁ High | Critical

    PMID 31044749 · one of two readings recorded this

  • positive findings rate

    no effect, p = 0.46

    There were no significant differences in the rate of positive findings comparing simethicone with water (RR = 1.13, 95%CI: 0.82–1.55, P = 0.46)

    PMID 31044749 · one of two readings recorded this

  • positive findings rate

    no effect, p = 0.71

    Similar results were observed with simethicone plus NAC versus simethicone (RR = 1.02, 95%CI: 0.90-1.16, P = 0.71)

    PMID 31044749 · one of two readings recorded this

  • procedure time

    decreases, p = 0.00001

    The procedure time in simethicone was shorter than that in water group (MD = −1.23 (−1.51, −0.96), P < 0.00001, I2= 31%)

    PMID 31044749 · one of two readings recorded this

  • procedure time

    no effect, p = 0.21

    Compared with water, simethicone plus NAC showed no significant difference (MD = −0.81 (−2.06, −0.44), P = 0.21, I2= 0%)

    PMID 31044749 · one of two readings recorded this

  • total mucosal visibility score at gastroscopy (four-point, three-point and other scales pooled), positive findings rate, procedure time and adverse events, simethicone plus NAC versus simethicone alone or water

    MD = -0.14 (-0.25, -0.03) for simethicone plus NAC versus simethicone alone, p = 0.01

    Not recorded as a finding: this platform holds no node for the endpoint

    Simethicone plus NAC showed better TMVS than simethicone alone (MD = −0.14 (−0.25, −0.03), P = 0.01, I2= 0%) without significant heterogeneity.

    PMID 31044749 · one of two readings recorded this

  • total mucosal visibility score at gastroscopy, simethicone plus NAC versus simethicone alone (simethicone given in both arms); also rate of positive findings and procedure time

    MD = −0.14 (−0.25, −0.03), p = 0.01

    Not recorded as a finding: this platform holds no node for the endpoint

    Simethicone plus NAC showed better TMVS than simethicone alone (MD = −0.14 (−0.25, −0.03), P = 0.01, I2= 0%) without significant heterogeneity.

    PMID 31044749 · one of two readings recorded this

  • total mucosal visibility score

    modulates, p = 0.00001

    Compared with water, simethicone displayed significant differences on TMVS with substantial heterogeneity (mean difference, MD = −3.62, (−4.65, −2.60), P < 0.00001, I2= 67%)

    PMID 31044749 · one of two readings recorded this

  • total mucosal visibility score

    modulates, p = 0.00001

    Simethicone plus NAC showed similar effect than water (MD = −3.29 (−4.38, −2.21), P < 0.00001, I2= 60%)

    PMID 31044749 · one of two readings recorded this

  • total mucosal visibility score

    modulates, p = 0.0004

    Removing the study by Asl et al. the heterogeneity reduced to low (I2= 28%), the meta-analysis result changed to: MD = −2.7 (−4.19, −1.22, P = 0.0004)

    PMID 31044749 · one of two readings recorded this

  • hospital length of stay

    no effect, p = 0.35, n = 1650

    1,650 patients for hospital length of stay (HLoS) (MD -0.21 days, 95% CI -0.64 to 0.23; I2 = 89%; p = 0.35)

    PMID 31071081 · one of two readings recorded this

  • intensive care unit length of stay

    no effect, p = 0.73, n = 1512

    1,512 patients for intensive care unit length of stay (ICULoS) (MD -0.04 days, 95% CI -0.29 to 0.20; I2 = 95%; p = 0.73)

    PMID 31071081 · one of two readings recorded this

  • intensive care unit length of stay

    decreases, p = 0.00001, n = 162

    enriched cardioplegia solution with NAC compared to SoC in intensive care unit length of stay (MD -0.63 days, 95% CI -0.88 to -0.38; n = 162; I2 = 84%; p < 0.00001)

    PMID 31071081 · one of two readings recorded this

  • acute myocardial infarction

    no effect, p = 0.55, n = 1178

    1,178 patients for acute myocardial infarction (RR 0.84, 95% CI 0.48 to 1.48; events (NAC:22/587, SoC:26/591); I2 = 0%; p = 0.55)

    PMID 31071081 · one of two readings recorded this

  • acute renal insufficiency

    no effect, p = 0.34, n = 1711

    1,711 patients for acute renal insufficiency (RR 0.92, 95% CI 0.79 to 1.09; events (NAC:180/886, SoC:193/845); I2 = 0%; p = 0.34)

    PMID 31071081 · one of two readings recorded this

  • arrhythmia

    no effect, p = 0.27, n = 886

    886 patients for arrhythmia (RR 0.79, 95% CI 0.52 to 1.20; events (NAC:81/446, SoC:98/440); I2 = 50%; p = 0.27)

    PMID 31071081 · one of two readings recorded this

  • cardiac insufficiency

    no effect, p = 0.38, n = 1149

    1,149 patients for cardiac insufficiency (RR 0.77, 95% CI 0.44 to 1.38; events (NAC:19/572; SoC:24/577); I2 = 0%; p = 0.38)

    PMID 31071081 · one of two readings recorded this

  • mortality, subgroups by route, dose, timing, technique and population

    no effect

    we found no statistically significant differences based on route, dose, timing of administration of NAC, surgical or anesthetic technique and characteristics of the population

    PMID 31071081 · one of two readings recorded this

  • mortality

    no effect, p = 0.23

    mortality (RR 0.71, 95% CI 0.40 to 1.25; events (NAC:20/870, SoC:33/867); I2 = 0%; p = 0.23)

    PMID 31071081 · one of two readings recorded this

  • acute exacerbation of COPD (AECOPD) risk

    decreases

    In the pairwise meta-analysis mucolytic/antioxidant agents significantly reduced the risk of AECOPD (RR 0.74 95%CI 0.68-0.80)

    PMID 31133026 · one of two readings recorded this

  • duration of acute exacerbation of COPD (AECOPD), network meta-analysis of erdosteine, carbocysteine and NAC; also risk of AECOPD and hospitalization

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01).

    PMID 31133026 · one of two readings recorded this

  • duration of acute exacerbation of COPD (AECOPD), risk of AECOPD and hospitalization due to AECOPD, network meta-analysis of erdosteine, carbocysteine and NAC

    decreases, significant reduction, P < 0.01 (no point estimate in the sentence)

    Not recorded as a finding: this platform holds no node for the endpoint

    Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01).

    PMID 31133026 · one of two readings recorded this

  • duration of AECOPD

    decreases, p = 0.01

    Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01)

    PMID 31133026 · one of two readings recorded this

  • duration of AECOPD

    decreases, p = 0.01

    Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01)

    PMID 31133026 · one of two readings recorded this

  • hospitalization due to AECOPD

    decreases, p = 0.05

    Only erdosteine reduced the risk of experiencing at least one AECOPD (P < 0.01) and the risk of hospitalization due to AECOPD (P < 0.05)

    PMID 31133026 · one of two readings recorded this

  • risk of at least one AECOPD

    decreases, p = 0.01

    Only erdosteine reduced the risk of experiencing at least one AECOPD (P < 0.01) and the risk of hospitalization due to AECOPD (P < 0.05)

    PMID 31133026 · one of two readings recorded this

  • Progression-free survival

    increases, p = 0.016

    PFD + NAC treatment showed favourable results regarding the PFS (median survival days 304 d vs 168 d; p = 0.016)

    PMID 32380989 · one of two readings recorded this

  • At least one side effect

    no effect, p = 0.314

    similar (PFD + NAC vs PFD alone: 41 vs 57, OR = 1.83, 95% CI 0.56–5.94, p = 0.314, Fig. 3a)

    PMID 32380989 · one of two readings recorded this

  • At least one side effect

    no effect, p = 0.592

    SE | 0.56–5.94 | 0.314 | 0.43–5.17 | 0.068 | 0.33–1.88 | 0.592

    PMID 32380989 · one of two readings recorded this

  • At least one side effect

    no effect, p = 0.068

    SE | 0.56–5.94 | 0.314 | 0.43–5.17 | 0.068 | 0.33–1.88 | 0.592

    PMID 32380989 · one of two readings recorded this

  • Change in 6MWD

    no effect, p = 0.54

    between the observational study (− 13.25 ± 6.77 vs − 16.59 ± 4.65, p = 0.159) and Behr’s RCT (− 4.3 vs − 11.7, p = 0.54)

    PMID 32380989 · one of two readings recorded this

  • Change in 6MWD

    no effect, p = 0.159

    between the observational study (− 13.25 ± 6.77 vs − 16.59 ± 4.65, p = 0.159) and Behr’s RCT (− 4.3 vs − 11.7, p = 0.54)

    PMID 32380989 · one of two readings recorded this

  • Change in DLco% predicted from baseline to week 24

    no effect, p = 0.58

    There was no difference in the ΔDLco% between the PFD + NAC group and the PFD group (SMD = 0.13, 95% CI -0.34-0.61, p = 0.580, Fig. 2b)

    PMID 32380989 · one of two readings recorded this

  • Change in DLco% predicted

    no effect, p = 0.73

    ΔDLco% | −0.34-0.62 | 0.580 | NA | NA | −2.44-2.22 | 0.730

    PMID 32380989 · one of two readings recorded this

  • Change in FVC% predicted from baseline to week 24

    no effect, p = 0.295

    PFD + NAC therapy had no additional benefit in reducing the decrease in lung function (SMD = -0.09, 95% CI − 0.86-0.69, p = 0.295, Fig. 2a)

    PMID 32380989 · one of two readings recorded this

  • Change in FVC% predicted

    no effect, p = 0.2

    ΔFVC% | -0.86-0.69 | 0.693 | NA | NA | −4.23-0.13 | 0.200

    PMID 32380989 · one of two readings recorded this

  • change in predicted DLco% from baseline to week 24, pooled standardised mean difference

    no effect, SMD 0.13; 95% CI -0.34 to 0.61, p = 0.58

    Not recorded as a finding: no outcome node for diffusing capacity for carbon monoxide

    There was no difference in the ΔDLco% between the PFD + NAC group and the PFD group (SMD = 0.13, 95% CI -0.34-0.61, p = 0.580, Fig. 2b).

    PMID 32380989 · one of two readings recorded this

  • change in predicted FVC% from baseline to week 24, pooled standardised mean difference

    no effect, SMD -0.09; 95% CI -0.86 to 0.69, p = 0.295

    Not recorded as a finding: no outcome node for forced vital capacity percent predicted

    The results showed that PFD + NAC therapy had no additional benefit in reducing the decrease in lung function (SMD = -0.09, 95% CI − 0.86-0.69, p = 0.295, Fig. 2a) compared to PFD alone.

    PMID 32380989 · one of two readings recorded this

  • change in predicted FVC (ΔFVC%) and predicted DLco (ΔDLco%) from baseline to week 24, PFD + NAC versus PFD alone, pooled SMD

    SMD = -0.09, 95% CI − 0.86-0.69, p = 0.295

    Not recorded as a finding: this platform holds no node for the endpoint

    The results showed that PFD + NAC therapy had no additional benefit in reducing the decrease in lung function (SMD = -0.09, 95% CI − 0.86-0.69, p = 0.295, Fig. 2a) compared to PFD alone.

    PMID 32380989 · one of two readings recorded this

  • Gastrointestinal side effects

    no effect, p = 0.811

    gastrointestinal (GI): 26 vs 47, I2 = 30.9%, p = 0.215, OR = 1.08, 95% CI 0.56–2.08, p = 0.811, Fig. 4a

    PMID 32380989 · one of two readings recorded this

  • Gastrointestinal side effects

    no effect, p = 0.475

    GI_SE | 0.56–2.08 | 0.811 | 0.46–1.83 | 0.249 | 0.33–1.68 | 0.475

    PMID 32380989 · one of two readings recorded this

  • Gastrointestinal side effects

    no effect, p = 0.249

    GI_SE | 0.56–2.08 | 0.811 | 0.46–1.83 | 0.249 | 0.33–1.68 | 0.475

    PMID 32380989 · one of two readings recorded this

  • intolerable side effects leading to treatment discontinuation, pooled odds ratio

    no effect

    Not recorded as a finding: the quoted sentence says intolerable side effects were at a similar frequency but never states discontinuation, so the withdrawal-due-to-adverse-events node is not self-evidently matched

    Patients receiving PFD + NAC therapy experienced intolerable side effects at a similar frequency as in those receiving PFD alone.

    PMID 32380989 · one of two readings recorded this

  • Intolerable side effects leading to treatment discontinuation

    no effect, p = 0.092, n = 100

    combined PFD + NAC therapy did not increase the risk of intolerable side effects (OR = 2.85, 95% CI 0.84–9.59, p = 0.092, Fig. 3b)

    PMID 32380989 · one of two readings recorded this

  • Intolerable side effects leading to treatment discontinuation

    no effect, p = 0.635

    Intole_SE | 0.84–9.59 | 0.092 | 0.52–8.32 | 0.955 | 0.31–6.78 | 0.635

    PMID 32380989 · one of two readings recorded this

  • Intolerable side effects leading to treatment discontinuation

    no effect, p = 0.955

    Intole_SE | 0.84–9.59 | 0.092 | 0.52–8.32 | 0.955 | 0.31–6.78 | 0.635

    PMID 32380989 · one of two readings recorded this

  • Skin side effects

    no effect, p = 0.162

    skin side effects: 12 vs 17, I2 = 0%, p = 0.769, OR = 1.91, 95% CI 0.77–4.71, p = 0.162, Fig. 4b

    PMID 32380989 · one of two readings recorded this

  • Skin side effects

    increases, p = 0.038

    Skin_SE | 0.77–4.71 | 0.162 | 0.74–4.88 | 0.611 | 1.14–77.52 | 0.038

    PMID 32380989 · one of two readings recorded this

  • Skin side effects

    no effect, p = 0.611

    Skin_SE | 0.77–4.71 | 0.162 | 0.74–4.88 | 0.611 | 1.14–77.52 | 0.038

    PMID 32380989 · one of two readings recorded this

  • All-cause in-hospital mortality

    decreases, p = 0.01

    all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01)

    PMID 33067289 · one of two readings recorded this

  • Contrast-associated acute kidney injury

    decreases, p = 0.01, n = 1710

    significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01)

    PMID 33067289 · one of two readings recorded this

  • requirement for dialysis after contrast exposure, pooled risk ratio

    no effect, RR 0.61; 95% CI 0.11 to 3.38, p = 0.24

    Not recorded as a finding: no outcome node for requirement for dialysis / renal replacement

    The estimated effects on the requirement for dialysis (RR 0.61, 95% CI 0.11 to 3.38, p=0.24) were not statistically significant.

    PMID 33067289 · one of two readings recorded this

  • requirement for dialysis, pooled risk ratio

    no effect, RR 0.61, 95% CI 0.11 to 3.38, p = 0.24

    Not recorded as a finding: no outcome node for dialysis requirement

    The estimated effects on the requirement for dialysis (RR 0.61, 95% CI 0.11 to 3.38, p=0.24) were not statistically significant.

    PMID 33067289 · one of two readings recorded this

  • Requirement for dialysis

    no effect, p = 0.24

    The estimated effects on the requirement for dialysis (RR 0.61, 95% CI 0.11 to 3.38, p=0.24)

    PMID 33067289 · one of two readings recorded this

  • Acute kidney injury after cardiac surgery

    no effect, n = 1242

    Overall results showed that the effect of NAC in preventing AKI after adult cardiac surgery was equivocal, as shown in Fig. 2 (OR: 0.84, 95% CI: 0.64–1.10)

    PMID 34732600 · one of two readings recorded this

  • Acute kidney injury after cardiac surgery

    no effect

    This is shown in Fig. 5 (OR: 1.01, 95% CI: 0.73–1.41) and Supplemental Fig. 1 (OR: 0.66, 95% CI: 0.32–1.36), respectively

    PMID 34732600 · one of two readings recorded this

  • Acute kidney injury after cardiac surgery

    no effect

    This is shown in Fig. 5 (OR: 1.01, 95% CI: 0.73–1.41) and Supplemental Fig. 1 (OR: 0.66, 95% CI: 0.32–1.36), respectively

    PMID 34732600 · one of two readings recorded this

  • Acute kidney injury after cardiac surgery

    no effect

    as shown in Fig. 3 (OR: 0.77, 95% CI: 0.56–1.07) and Fig. 4 (OR: 1.10, 95% CI: 0.64–1.89), respectively

    PMID 34732600 · one of two readings recorded this

  • Acute kidney injury after cardiac surgery

    no effect

    as shown in Fig. 3 (OR: 0.77, 95% CI: 0.56–1.07) and Fig. 4 (OR: 1.10, 95% CI: 0.64–1.89), respectively

    PMID 34732600 · one of two readings recorded this

  • acute kidney injury incidence after cardiac surgery, pooled OR across 10 trials with differing AKI definitions (creatinine rise or AKIN)

    OR: 0.84, 95% CI: 0.64–1.10

    Not recorded as a finding: primary outcome. Overall sentence says the effect was equivocal and the next sentence omits the AKI object; no two-sided statement with the compound and endpoint in one sentence

    Overall results showed that the effect of NAC in preventing AKI after adult cardiac surgery was equivocal, as shown in Fig. 2 (OR: 0.84, 95% CI: 0.64–1.10).

    PMID 34732600 · one of two readings recorded this

  • In-hospital mortality

    no effect, n = 1055

    Meta-analytic estimates for in-hospital mortality showed that there was no statistically significant difference between patients treated with NAC and without, as shown in Supplemental Fig. 6 (OR: 0.85, 95% CI: 0.43–1.68)

    PMID 34732600 · one of two readings recorded this

The whole record — 920 rows